Company / Current Assets
Arcadia Biosciences, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$6.4M
FY2025
5-year range
$6.4M / $35.4M
FY2021-FY2025
Trend
-31.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 4 consecutive years, from $35M in FY2021 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -27.5%.
Declined from $15M to $6M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -37.0%
- 5-Year CAGR
- -27.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s current assets has declined for 4 consecutive years.
- 5-year CAGR of -27.5%, indicating a declining trend.
- In FY2025, current assets decreased 31.2% year-over-year.
- Peak current assets was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.4M | -31.2% |
| FY2024 | $9.2M | -38.3% |
| FY2023 | $15.0M | -41.1% |
| FY2022 | $25.4M | -28.2% |
| FY2021 | $35.4M | +11.6% |
| FY2020 | $31.7M | +11.4% |
| FY2019 | $28.4M | +24.3% |
| FY2018 | $22.9M | +52.0% |
| FY2017 | $15.0M | -71.2% |
| FY2016 | $52.2M | +0.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026